Exelixis, Inc. (EXEL) Announces Second Quarter 2013 Financial Results  
8/7/2013 7:22:50 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended June 30, 2013.

Q2 2013 Highlights and Recent Events

•Reported net product revenue for COMETRIQ® (cabozantinib) of $4.0 million in the second quarter of 2013.

•Expanded the sales force to 14 representatives.

Hey, check out all the research scientist jobs. Post your resume today!